Summary The clinicopathological characteristics of breast cancer in 95 women between the ages of 24 and 45 years with a family history of breast cancer were compared with tumours from 329 women with sporadic disease matched for age and year of diagnosis. There was a trend for the family history patients to have slightly smaller tumours (mean size 2.49 cm) than the controls (mean 3.04 cm) (Mann-Whitney test, P= 0.09). A significantly greater proportion of the familial cases had grade IlIl infiltrating ductal carcinoma than did the controls (40% vs 27%; 2= 5.64, P = 0.02). Despite this, there were more cases of operable node-negative disease among the study group than among the controls (48% vs 32%; X2 = 8.2, P = 0.004). There was a highly significant survival advantage for patients with a family history (X2 = 22.4, P < 0.001).
The prognostic significance of breast cancer morphology has been reviewed extensively. In contrast, there are few studies that have examined the association between breast cancer histopathology and a family history of breast cancer (Rosen et al, 1982; Claus et al, 1993; Fukutomi et al, 1993) . There are, however, several anecdotal reports of improved survival rates in patients with a family history of breast cancer (Lynch et al, 1981; Albano et al, 1982) . The few studies carried out since the identification of the BRCAJ gene have reported a more favourable prognosis for patients from BRCAI-linked breast/ovarian cancer families (Malone et al, 1996; Marcus et al, 1996; Rubin et al, 1996) .
We have examined the histological characteristics of breast cancer in women with and without a positive family history to determine whether familial breast cancers had features similar to or distinct from sporadic forms. The issue of an improved clinical outcome has also been explored in this study to determine whether or not a family history confers a survival advantage to women with breast cancer.
METHODS
A review of all women with breast cancer diagnosed below the age of 45 years at the ICRF Clinical Oncology Unit or referred to the SE Thames Regional Genetics Centre at Guy's Hospital between June 1965 and December 1995 was undertaken. Detailed pedigree data were obtained to determine the extent of a hereditary predisposition Received 3 June 1997 Revised 1 December 1997 Accepted 8 December 1997 Correspondence to: SN Mohammed in these women. A total of 95 breast cancer families were ascertained through a proband diagnosed with breast cancer at or below 45 years. Six probands had two or more first-degree and seconddegree affected relatives, 37 had one first-and one second-degree affected relatives, 27 had only one first-degree affected relative, while 25 had only second-degree affected relatives. Of the entire study cohort, nine patients were from breast/ovarian cancer families.
The clinical and pathological characteristics of these 95 patients diagnosed between the ages of 21 and 45 years and 329 agematched controls, i.e. women diagnosed with breast cancer but with no family history of breast cancer on specific enquiry, were examined. The controls were matched with the 95 cases for age and year of diagnosis. Attempts were made to find four matched controls for each case, but in 37 probands this was not possible. In ten of these cases, the women were below the age of 30, and 22 were diagnosed in the past 5 years. For 26 cases, it was possible to obtain only three controls; for seven cases, two matched controls and for four cases only one matched control were possible. The cases and controls were examined for the distribution of background risk factors, clinical and pathological features and relapsefree and overall survival in all 424 patients (95 cases, 329 controls). We also examined overall and relapse-free survival in two subgroups: 309 women with invasive operable breast cancer with known node status (77 cases, 232 controls) and a subset of 196 of these women with invasive operable disease who were diagnosed and treated in the Imperial Cancer Research Fund Clinical Oncology Unit at Guy's Hospital, London (55 cases, 141 controls).
The patients have been followed up for a median of 8.6 years (range 1 month-30 years). Pathological details of the breast cancers were taken from the histopathology results. The tumours from the 196 patients diagnosed at Guy's Hospital were typed according to WHO criteria (1980) , and histological grade was determined according to the criteria of Bloom and Richardson (as modified by Elston) (Elston, 1984) .
Statistical methods
The chi-squared test was used for comparison of categorical variables. Survival curves were produced using the method of Kaplan and Meier (Kaplan and Meier, 1985) . Differences between survival curves were determined using the log-rank test (Peto et al, 1975) . Multivariate analysis was performed using the Cox proportional hazards model (Cox, 1972) . Table 1 shows a comparison of the presentation characteristics of the 95 patients in the family history group and the 329 patients in the control group. No statistically significant differences were noted between the two groups, although there was a trend for patients with a family history to have clinically smaller tumours (mean size 2.49 cm) than the controls (mean 3.04 cm) (Mann-Whitney test, P = 0.09).
RESULTS

Comparison of presentation characteristics
Pathological features
The pathological features at presentation are shown in Table 2 . A greater proportion of the familial cases had operable node-negative disease, 48% vs 32% (XI = 8.2, P = 0.004). Comparing the 309 women with invasive operable disease in whom nodal status was known, the number of node-negative cases was still significantly greater in the study group (55% vs 40%, XI = 4.3, P = 0.04). Of the patients with infiltrating ductal carcinoma, there were significantly more grade III tumours in the familial group (40% vs 27%, %2 = 5.64, P = 0.02).
Survival Univariate analysis
The median follow-up times for the study and control groups were 7.8 (range 8.6 months-30 years) and 8.6 years (range 1 month-29 years) respectively. The study group had a significantly better prognosis than the control cases. Figure 1 shows the difference in overall survival between the two groups (x2, = 22.4, P < 0.001 (1996) of 175 breast carcinomas in women from 52 families (26 of which were linked to BRCAI) and 187 breast carcinomas from women without a family history similarly found a non-significant trend towards better survival with fewer recurrences in the family history group as a whole, without adjustment for age and stage at diagnosis. Within the family history group, the BRCAI-related patients had fewer recurrences than other hereditary breast cancer patients (P = 0.0 13). This was despite the fact that the BRCAl-related tumours, although having a lower DNA index, showed greater proliferative activity in terms of mitotic grade and S-phase fraction. Similarly, Malone et al (1996) , in an analysis of 733 cases, found that the risk of dying among affected women who had a first-degree family history of breast cancer was half that of women with no family history. Additionally, the difference in survival rates could not be attributed to differences in screening or treatment between the two groups. A major strength of the latter study was that it had a population-based design, which therefore minimized a selection bias for women with varying family histories. The multicentre British Journal of Cancer (1998) 77(12) study of Rubin et al (1996) of 53 patients with ovarian cancer and germline BRCAJ mutations in patients with advanced-stage disease similarly reports a significantly more favourable outcome for the familial cases in comparison to sporadic ovarian cancers. The actuarial median survival for 43 of their patients with a defined BRCAJ mutation was 77 months compared with 29 months for matched controls (P < 0.001).
There are clearly inherent limitations in the current study, as with other retrospective studies reported in the literature. A fact highlighted in a recent correspondence in the New England Journal of Medicine (Canistra et al, 1997) , after the publication of the paper by Rubin et al (1996) . We have tried to overcome many of the problems raised by the selection of our control group, which was matched for stage of disease and year of diagnosis. Although not all patients were treated in our unit for the duration of their disease, the outcome for the different groups was similar. Despite the best efforts to avoid selection bias, the only way to overcome them is by a large prospective study that compares the outcome of known BRCAJIBRCA2 carriers with non-mutation carriers. Our results need to be interpreted in the light of a relatively short median follow-up time of 8.6 years. Some of the younger patients (below 30 years) were diagnosed recently and, consequently, have made a lesser contribution to the overall survival analysis. It will therefore be important to reanalyse the data in 5 years, when a longer followup time will have elapsed for the patients in this study. It is not known whether the presence of a family history contributed to earlier diagnosis of breast cancer in the study group. Such knowledge might lead to increased vigilance, resulting in more biopsies for benign disease and more frequent mammograms. Unfortunately, such data were not available for many patients. Nevertheless, a clear effect on survival rates was seen in the study group even after adjusting for differences in features, such as tumour size, stage and nodal involvement, between the two groups.
Some recent reports (Bignon et al, 1995; Jacquemier et al, 1995; Marcus et al, 1996) have highlighted an association between grade III ductal carcinomas and female BRCAJ gene carriers. Loss of heterozygosity (LOH) analyses have shown consistent loss of the wild-type allele on 17q in breast tumours from families linked to BRCA]. Interestingly, a high rate of LOH at the BRCA2 locus has also been shown in one family with a pathogenic BRCAJ mutation that had prior evidence of 17q LOH (Kelsell et al, 1996) . An analysis of 118 unselected cases of primary breast tumours showed an excess of carcinomas concordant for loss or retention at both BRCAJ and BRCA2 loci in grade III tumours but not in grade I or II ductal carcinomas. These observations suggest a combined role for BRCA] and BRCA2 in the tumorigenic pathway, particularly in grade III tumours (Kelsell et al, 1996) . Patients with combined loss at both loci also appeared to have a better survival rate than those with loss at only one locus (D Barnes, personal communication, 1996) .
At present, it is not known what proportion of breast cancer cases in our study group may be attributable to an underlying mutation in the BRCAI or BRCA2 genes, although this is currently being ascertained. A preliminary search for constitutional BRCAJ mutations in 55 of these families has found such mutations to be implicated not only in the larger families but also in some smaller kindreds. To date, six definite pathogenic BRCAI mutations have been defined in the study group. Two of the mutations were found in nine sporadic cases screened so far (Greenman et al, 1998) . Furthermore, there may be some unrecognized mutation carriers among our control group of patients. If this was so, and their outcome was similar to that of the familial patients, the difference between our two groups would be even larger.
These preliminary data from 95 patients with familial breast cancer and 329 age-matched controls suggest that a family history is significantly related to improved prognosis in women with breast cancer. The familial cases had higher grade tumours at presentation but, despite this, had less nodal involvement and significantly better overall and relapse-free survival rates. The precise mechanism that could account for a better prognosis in the familial cases is unclear. It is important that it is investigated in future studies with a longer follow-up. These will need to address whether or not these observed differences in survival rates reveal a true pathobiological difference in tumour behaviour and, if so, how these relate to underlying BRCA]/2 mutations. If particular mutations are associated with a less aggressive nature of some tumours or a better response to chemotherapy, it is conceivable that this may account for the improved survival rates observed. Clarification of this and the role of other breast cancer susceptibility genes in the tumorigenic pathway is likely to have an important bearing on the counselling of women from such high-risk breast cancer families.
